| |
BioIVT has been adding more standardized products, search and page enhancements, no-touch online quoting and ordering options, and have more improvements on the way. Explore BioIVT.com >> 
|
|
Today’s Big NewsJun 26, 2024 |
| By Nick Paul Taylor A death and other adverse events have forced Lyell Immunopharma to take a two-track approach to its early-phase CAR-T clinical trial, holding back dose escalation in people with lung metastases while racing ahead in the wider population. |
|
|
|
By Gabrielle Masson Venture capital firm Curie.Bio has fueled up, raising $380 million for biotech founders and promising to stretch the runway of seed money for better long-term results. |
By James Waldron Megarounds have been few and far between in 2024, but Formation Bio has managed to draw in an impressive $372 million series D as the AI-focused biotech seeks to expand its pipeline. |
Sponsored by Cardinal Health CGT companies should consider developing a market access strategy early in clinical development, ideally more than three years prior to launch. |
By Nick Paul Taylor With two cardiovascular disease candidates in or near phase 3, RNAi specialist Arrowhead Pharmaceuticals has dropped one prospect and thrown its weight behind the other to manage its spending. |
By Annalee Armstrong Intellia Therapeutics doesn’t need to redose patients with a CRISPR gene edited therapy for transthyretin (ATTR) amyloidosis. But new data suggests it could be done. |
By Helen Floersh The Biospecimen Management Consortium will see major players in Big Pharma aim to establish best practices for handling patients’ biological samples, or biospecimen, during clinical trials. |
By Conor Hale BillionToOne said the proceeds will help scale up its blood testing businesses in prenatal screening and cancer. |
By Fraiser Kansteiner As other immunology players make inroads into the giant cell arteritis arena, one of Johnson & Johnson’s top-grossing medicines, Tremfya, has come up short in the disease. |
By Noah Tong Arkansas says Optum and Express Scripts have not adequately protected consumers from the dangers of opioids, instead using their profits to grow into vertically integrated giants. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker sits down with Bobby Sheng, the CEO of Bora Pharmaceuticals, to discuss the concept of “friend-shoring” in drug manufacturing. |
|
|---|
|
|
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Webinar Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
Whitepaper New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
Whitepaper This detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data. Sponsored by: Privacy Analytics, an IQVIA company |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
